A vertically integrated molecular oncology laboratory in South India. IHC, FISH, qPCR, Sanger, targeted NGS, liquid biopsy, hereditary panels and comprehensive genomic profiling — every test on our own platform.
Cancer care has moved to precision medicine — but diagnostics infrastructure hasn't kept pace.
new cancer cases in India annually; ~70% diagnosed at advanced stages where genomic testing is required.
higher average revenue per test for advanced oncology assays vs. routine pathology.
labs in India hold CAP certification as of 2026; fewer still run a full precision-oncology menu in-house.
typical turnaround time for ship-out NGS samples — delaying treatment decisions for oncologists.
Every test — from sample receipt to oncologist-ready report — performed on our own platform.
IHC, FISH, qPCR, Sanger, targeted and broad NGS, liquid biopsy, hereditary cancer panels, TMB, MSI, HRR and comprehensive genomic profiling — no ship-out for any test.
3–5 days for NGS vs. 7–10+ days for ship-out labs. 24 hours for IHC and qPCR. Faster TAT is a structural oncologist-acquisition advantage.
LIMS-driven QC gates at every step — extraction, library prep, sequencing, variant calling, reporting. Monthly re-run budgets embedded in COGS.
In-house COGS at 35–42% of revenue delivers 58–65% gross margin vs. ~50–52% for ship-out lab models.
| Segment | 2026 Estimate | Forecast | CAGR |
|---|---|---|---|
| India cancer diagnostics (overall) | USD 4.56 Bn (2024) | USD 8.12 Bn by 2030 | 10.2% |
| India tumour biomarker assay | USD 320–380 Mn | USD 1.1–1.5 Bn by 2035 | 14–17% |
| Liquid biopsy share | 12–15% | 18–22% by 2035 | Fastest-growing |
| NGS comprehensive profiling share | 18–22% | 25–30% by 2035 | Cost deflation |
Targeting breast, lung, colorectal and haematological cancers in South India (Hyderabad, Bangalore, Chennai corridors) and referring Tier 2 cities. These cancers carry established biomarker guidelines and the largest molecular testing demand.
Year-3 target of 650–800 tests/month — less than 1% of national biomarker testing volume, but a concentrated, high-value position in the South India private oncology market.
| Metric | Value |
|---|---|
| Average revenue per test | ₹28,000 |
| Direct cost per test (in-house) | ₹9,800 |
| Gross margin per test | ₹18,200 (65%) |
| Logistics + counselling | ₹600 |
| Contribution margin / test | ₹17,600 (63%) |
₹ Lakh. Base case with a phased volume ramp and NABL accreditation at Month 8.
| Line Item (₹ Lakh) | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Tests per month (avg.) | 80 | 275 | 650 |
| Annual test volume | 960 | 3,300 | 7,800 |
| ARPT (₹) | 26,000 | 27,000 | 28,000 |
| Revenue | 249.6 | 891.0 | 2,184.0 |
| Direct costs (COGS) | 104.8 | 338.6 | 764.4 |
| Gross profit | 144.8 | 552.4 | 1,419.6 |
| Gross margin | 58% | 62% | 65% |
| Manpower | 90.0 | 168.0 | 280.0 |
| Rent & utilities | 24.0 | 36.0 | 48.0 |
| Marketing & doctor engagement | 24.0 | 54.0 | 96.0 |
| Accreditation, QA, legal | 15.0 | 18.0 | 24.0 |
| Other admin, logistics, cloud | 12.0 | 34.0 | 112.0 |
| Total opex | 165.0 | 310.0 | 560.0 |
| EBITDA | (20.2) | 242.4 | 859.6 |
| EBITDA margin | -8% | 27% | 39% |
| Player Type | Examples | Our Advantage |
|---|---|---|
| National reference labs | MedGenome, Strand, Metropolis | Locally responsive, faster TAT, direct oncologist relationship, single-owner QC |
| Hospital-integrated labs | Tertiary cancer centres | Serve multiple hospitals; no single-hospital dependency |
| Routine pathology chains | Regional labs | Molecular oncology depth, NGS + CGP + counselling |
| Ship-out / outsourced labs | Small regional labs | We capture the full margin and control turnaround |
| Role | Profile | Timing |
|---|---|---|
| Founder / CEO | Diagnostics or healthcare operations background; South India oncology network | At inception |
| Molecular Pathologist / Lab Director | MD Pathology with molecular oncology experience; NABL signatory | Advisory Yr 1, full-time Yr 2 |
| NGS Scientists (2) | MSc/PhD with Illumina or MGI library prep + sequencing experience | Month 3–4 |
| Bioinformatician | Variant calling, annotation, ACMG classification, LIMS integration | Month 4–5 |
| Head of Sales (Oncology) | Existing relationships with 50+ oncologists in South India | Month 1–3 |
| Genetic Counsellors (2) | Board-certified / trained in cancer genetics | Month 3–6 |
| Quality Manager | NABL / ISO 15189 implementation experience | Month 6–9 |
| Advisory Board | Medical oncologist, surgical oncologist, pharma biomarker expert | Formalise before close |
Heavy capex, lean operating buffer, and a fast path to NABL accreditation and revenue.
| Use of Funds | ₹ Cr | % | Details |
|---|---|---|---|
| Laboratory capex — build-out + equipment | 2.97 | 66% | Sequencer, extraction, qPCR, IHC, QC suite, LIMS, lab build |
| NABL, validation, SOPs, legal, insurance | 0.30 | 7% | Validation studies, proficiency testing, consultants |
| Working capital & operating buffer | 1.23 | 27% | 12–15 months of operating cash burn |
| Total | 4.50 | 100% |
NABL-accredited in-house lab live
20–30 oncologist relationships; 5–8 collection centres
₹2.5 Cr+ revenue run-rate
EBITDA-positive operations
We welcome conversations with seed investors, family offices, and strategic partners in Indian oncology and diagnostics.